Free Research Reports on These Medical Supplies Stocks -- Hill-Rom, NeuroMetrix, Akers Biosciences, and Antares Pharma

NEW YORK, March 21, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.  Today we are offering reports on HRC, NURO, AKER, and ATRS which can be accessed for free by signing up to www.wallstequities.com/registration. WallStEquities.com turns investors' attention to the Medical Instruments and Supplies Manufacturing industry, which primarily researches, develops, and produces nonelectronic medical, surgical, dental, and veterinary instruments and apparatus, such as syringes, anesthesia apparatus, and blood transfusion equipment. In this morning's lineup are these four equities: Hill-Rom Holdings Inc. (NYSE: HRC), NeuroMetrix Inc. (NASDAQ: NURO), Akers Biosciences Inc. (NASDAQ: AKER), and Antares Pharma Inc. (NASDAQ: ATRS). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Hill-Rom Holdings

Chicago, Illinois headquartered Hill-Rom Holdings Inc.'s stock finished Tuesday's session 1.13% higher at $87.18 with a total trading volume of 398,394 shares. Over the last month and the previous three months, the Company's shares have advanced 5.15% and 4.72%, respectively. Additionally, the stock has gained 24.81% over the past year. Shares of the Company are trading above their 50-day and 200-day moving averages by 2.02% and 7.98%, respectively. Moreover, shares of Hill-Rom, which operates as a medical technology company worldwide, have a Relative Strength Index (RSI) of 56.81.  

On March 15^th, 2018, Hill-Rom announced that it will host its Q2 FY18 earnings conference call and webcast on April 27^th, 2018, beginning at 8:30 a.m. ET. A simultaneous webcast of the call will be accessible on the Company's website.  Get the full research report on HRC for free by clicking below at:

www.wallstequities.com/registration/?symbol=HRC

NeuroMetrix

Shares in Waltham, Massachusetts headquartered NeuroMetrix Inc. declined 1.54%, ending yesterday's session at $1.45 with a total trading volume of 44,701 shares. The stock has gained 10.48% in the past month. The Company's shares are trading 8.03% below their 50-day moving average. Moreover, shares of NeuroMetrix, which develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders, has an RSI of 44.48. Find your free research report on NURO at:

www.wallstequities.com/registration/?symbol=NURO

Akers Biosciences

On Tuesday, Thorofare, New Jersey headquartered Akers Biosciences Inc.'s stock rose slightly by 0.10%, to close the day at $0.82. A total volume of 17.07 million shares was traded. The Company's shares have skyrocketed 105.30% in the last month and 100.20% in the previous three months. The stock is trading 86.66% and 7.49% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Akers Biosciences, which together with its subsidiaries, focuses on the development and sale of disposable diagnostic testing devices to facilitate time sensitive therapeutic decisions in the US and internationally, have an RSI of 71.92. 

On March 15^th, 2018, Akers Biosciences announced that it will hold a conference call on March 29^th, 2018, at 9:00 a.m. ET to discuss its earnings for the fiscal year ended December 31^st, 2017. Management will be available during a question-and-answer session. Sign up today for the free research report on AKER at:

www.wallstequities.com/registration/?symbol=AKER

Antares Pharma

Shares in Ewing, New Jersey headquartered Antares Pharma Inc. ended the day 3.02% lower at $2.25. A total volume of 1.21 million shares was traded. The stock has gained 11.94% in the previous three months. The Company's shares are trading below their 50-day moving average by 0.54%. Furthermore, shares of Antares Pharma, which focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide, have an RSI of 43.63. 

On March 13^th, 2018, Antares Pharma reported its Q4 and full-year 2017 results. For Q4 2017, total revenue was $14.0 million, operating expenses were $11.0 million, and net loss was $(3.7) million. For the full year, total revenue was $54.5 million, operating expenses were $43.5 million, and net loss was $(16.7) million. At December 31^st, 2017, cash, cash equivalents, and investments were $31.6 million. Wall St. Equities' research coverage also includes the downloadable free report on ATRS at:

www.wallstequities.com/registration/?symbol=ATRS

--

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are
covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Wall St. Equities

Related Links

http://www.wallstequities.com